Granite Bio AG products

Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.

Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.